These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9863888)

  • 1. Adherence to combination antiretroviral therapy assessed by anonymous patient self-report.
    Walsh JC; Dalton M; Gazzard BG
    AIDS; 1998 Dec; 12(17):2361-3. PubMed ID: 9863888
    [No Abstract]   [Full Text] [Related]  

  • 2. Virological failure and adherence to antiretroviral therapy in HIV-infected patients.
    Rodríguez-Rosado R; Jiménez-Nácher I; Soriano V; Antón P; González-Lahoz J
    AIDS; 1998 Jun; 12(9):1112-3. PubMed ID: 9662214
    [No Abstract]   [Full Text] [Related]  

  • 3. Patient adherence, not viral load now most important in HIV therapy.
    Rep Med Guidel Outcomes Res; 2000 Feb; 11(3):6-7. PubMed ID: 11768406
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiviral treatment of HIV infection.
    Thomas MG; Ellis-Pegler RB
    N Z Med J; 1998 Sep; 111(1074):353-4. PubMed ID: 11039818
    [No Abstract]   [Full Text] [Related]  

  • 5. Another take on when to start and how to succeed.
    Friedland GH
    AIDS Clin Care; 2001 Sep; 13(9):82. PubMed ID: 11547600
    [No Abstract]   [Full Text] [Related]  

  • 6. Standard treatments for HIV, Spring 1997.
    Smith D
    AIDS Treat News; 1997 Apr; (No 269):4-5. PubMed ID: 11364255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. State of the art: antiretroviral and prophylactic treatments in HIV/AIDS.
    Porche DJ
    Nurs Clin North Am; 1999 Mar; 34(1):95-112. PubMed ID: 9922281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage therapy for patients failing their current antiretroviral regimen.
    Albrecht MA
    AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
    [No Abstract]   [Full Text] [Related]  

  • 9. The year in review: antiretroviral treatment.
    Hirschel B; Opravil M
    AIDS; 1999; 13 Suppl A():S177-87. PubMed ID: 10885775
    [No Abstract]   [Full Text] [Related]  

  • 10. Once-daily therapies.
    Carey D
    J HIV Ther; 2003 Feb; 8(1):7-11. PubMed ID: 12840708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral update: recent advances expand options for patients with HIV.
    Santhanam H; Goins M
    Adv Nurse Pract; 2004 Nov; 12(11):53-4, 56. PubMed ID: 15559568
    [No Abstract]   [Full Text] [Related]  

  • 12. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 13. Teaching adherence to substance users.
    TreatmentUpdate; 2002; 14(4):4-5. PubMed ID: 12064315
    [No Abstract]   [Full Text] [Related]  

  • 14. Vaccination and HIV-1 replication during highly active antiretroviral therapy.
    Kroon FP; Beersma MF; Kroes AC; Groeneveld PH; van Dissel JT
    AIDS; 1999 Jan; 13(1):135-6. PubMed ID: 10207556
    [No Abstract]   [Full Text] [Related]  

  • 15. Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART.
    Antinori A; Cozzi-Lepri A; Ammassari A; Trotta MP; Nauwelaers D; Hoetelmans R; Murri R; Melzi S; Narciso P; Nasta P; Zaccarelli M; Santopadre P; Vecchiet J; Izzo CM; Maonforte Ad;
    Antivir Ther; 2004 Apr; 9(2):291-6. PubMed ID: 15134192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors.
    Tavel JA; Miller KD; Masur H
    Clin Infect Dis; 1999 Mar; 28(3):643-76. PubMed ID: 10194094
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV resistance: the new enemy.
    Colvin R
    Common Factor; 1997 Nov; (No 11):6-7. PubMed ID: 11364845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy.
    Müller AD; Myer L; Jaspan H
    Clin Infect Dis; 2009 Jan; 48(1):e3-5. PubMed ID: 19025495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.
    Masquelier B; Pereira E; Peytavin G; Descamps D; Reynes J; Verdon R; Fleury H; Garraffo R; Chêne G; Raffi F; Brun-Vézinet F;
    J Clin Virol; 2005 May; 33(1):75-8. PubMed ID: 15797369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.